Tin tức & Cập nhật

Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.

For women with polycystic ovary syndrome (PCOS), if a 5-day letrozole regimen for ovulation induction does not work, extending the duration of treatment may do the job, as shown in a study.

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

The use of the combination of palbociclib plus an aromatase inhibitor (AI) in the first-line treatment setting appears to confer survival advantage on patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC), according to real-world data.

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.